vancomycin has been researched along with rifaximin in 6 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 3 (50.00) | 29.6817 |
2010's | 2 (33.33) | 24.3611 |
2020's | 1 (16.67) | 2.80 |
Authors | Studies |
---|---|
Galang, MA; Gerding, DN; Hecht, DW; Johnson, S; Osmolski, JR; Sambol, SP | 1 |
Cloud, JW; Espinoza, D; Kelly, CP; Kokkotou, E; Michos, A; Moss, AC; Mustafa, N; O'Brien, M; Pothoulakis, C | 1 |
Finegold, SM; Molitoris, D; Väisänen, ML | 1 |
Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
Botta, M; D'Agostino, I; De Luca, F; Del Prete, R; Deodato, D; Docquier, JD; Ferraro, T; Guglielmi, MB; Mancini, A; Pasero, C; Sannio, F; Truglio, GI; Visaggio, D; Visca, P; Zamperini, C | 1 |
Chen, J; Ding, C; Doyle, T; Duncan, L; Ebright, RH; He, S; Lin, W; Liu, Y; Lynch, AS; Ma, Z; Molodtsov, V; Nguyen, P; Pulse, M; Robertson, GT; Wang, H; Weiss, WJ; Xu, X; Yuan, Y; Zhuang, Z | 1 |
1 review(s) available for vancomycin and rifaximin
Article | Year |
---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
5 other study(ies) available for vancomycin and rifaximin
Article | Year |
---|---|
In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004.
Topics: Anti-Bacterial Agents; Bacterial Toxins; Clostridioides difficile; Drug Resistance, Bacterial; Enterocolitis, Pseudomembranous; Humans; Microbial Sensitivity Tests; United States | 2007 |
Comparative efficacies of rifaximin and vancomycin for treatment of Clostridium difficile-associated diarrhea and prevention of disease recurrence in hamsters.
Topics: Animals; Anti-Infective Agents; Clostridioides difficile; Cricetinae; Diarrhea; Enterocolitis, Pseudomembranous; Humans; Mesocricetus; Rifamycins; Rifaximin; Treatment Outcome; Vancomycin; Weight Gain | 2008 |
Study of the in vitro activities of rifaximin and comparator agents against 536 anaerobic intestinal bacteria from the perspective of potential utility in pathology involving bowel flora.
Topics: Ampicillin; Bacteria, Anaerobic; Feces; Microbial Sensitivity Tests; Neomycin; Nitro Compounds; Rifamycins; Rifaximin; Sulbactam; Teicoplanin; Thiazoles; Vancomycin | 2009 |
Alkyl-guanidine Compounds as Potent Broad-Spectrum Antibacterial Agents: Chemical Library Extension and Biological Characterization.
Topics: Alkylation; Anti-Bacterial Agents; Caco-2 Cells; Guanidine; Humans; Microbial Sensitivity Tests; Permeability; Structure-Activity Relationship | 2018 |
Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens.
Topics: Anaerobiosis; DNA-Directed RNA Polymerases; Helicobacter Infections; Helicobacter pylori; Humans; Nitroimidazoles; Rifamycins | 2022 |